Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. Yian Lin , Adam X Maihofer , Emma Stapp , Megan Ritchey , Ney Alliey-Rodriguez , Amit Anand , Yokesh Balaraman , Wade H Berrettini , Holli Bertram , Abesh Bhattacharjee , Cynthia V Calkin , Carla Conroy , William Coryell , Nicole D'Arcangelo , Anna DeModena , Joanna M Biernacka , Carrie Fisher , Nicole Frazier , Mark Frye , Keming Gao , Julie Garnham , Elliot Gershon , Kara Glazer , Fernando S Goes , Toyomi Goto , Elizabeth Karberg , Gloria Harrington , Petter Jakobsen , Masoud Kamali , Marisa Kelly , Susan G Leckband , Falk W Lohoff , Andrea Stautland , Michael J McCarthy , Melvin G McInnis , Francis Mondimore , Gunnar Morken , John I Nurnberger , Ketil J Oedegaard , Vigdis Elin Giever Syrstad , Kelly Ryan , Martha Schinagle , Helle Schoeyen , Ole A Andreassen , Marth Shaw , Paul D Shilling , Claire Slaney , Bruce Tarwater , Joseph R Calabrese , Martin Alda , Caroline M Nievergelt , Peter P Zandi , John R Kelsoe Bipolar disorders（2021）
Abstract
In this PGBD Study of lithium response, several clinical features were found to be associated with failure to respond to lithium. Future validation is needed to confirm these clinical predictors of treatment failure and their use clinically to distinguish who will do well on lithium before starting pharmacotherapy.
More Translated text
Key words
bipolar disorder, clinical predictor, lithium, treatment response
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
